SciClone Pharmaceuticals Inc. (SCLN) Shares Down 20.6%
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) shares dropped 20.6% on Tuesday . The company traded as low as $10.25 and last traded at $10.53, with a volume of 953,768 shares. The stock had previously closed at $13.26.
The firm has a 50-day moving average price of $13.39 and a 200-day moving average price of $11.22. The firm has a market cap of $530.53 million and a price-to-earnings ratio of 19.69.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 EPS for the quarter. The business had revenue of $36.50 million for the quarter, compared to the consensus estimate of $33.60 million. On average, equities research analysts anticipate that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.
Other hedge funds and institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its position in shares of SciClone Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,559,182 shares of the specialty pharmaceutical company’s stock valued at $23,544,000 after buying an additional 53,987 shares during the last quarter. Matarin Capital Management LLC purchased a new position in shares of SciClone Pharmaceuticals during the fourth quarter valued at about $1,600,000. Cornerstone Capital Management Holdings LLC. raised its position in shares of SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock valued at $1,827,000 after buying an additional 48,470 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock valued at $2,991,000 after buying an additional 54,227 shares during the last quarter.
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.